» Articles » PMID: 22857878

Polydrug Abuse: a Review of Opioid and Benzodiazepine Combination Use

Overview
Publisher Elsevier
Specialty Psychiatry
Date 2012 Aug 4
PMID 22857878
Citations 238
Authors
Affiliations
Soon will be listed here.
Abstract

This paper reviews studies examining the pharmacological interactions and epidemiology of the combined use of opioids and benzodiazepines (BZDs). A search of English language publications from 1970 to 2012 was conducted using PubMed and PsycINFO(®). Our search found approximately 200 articles appropriate for inclusion in this paper. While numerous reports indicate that the co-abuse of opioids and BZDs is ubiquitous around the world, the reasons for the co-abuse of these medications are not entirely clear. Though the possibility remains that opioid abusers are using BZDs therapeutically to self-medicate anxiety, mania or insomnia, the data reviewed in this paper suggest that BZD use is primarily recreational. For example, co-users report seeking BZD prescriptions for the purpose of enhancing opioid intoxication or "high," and use doses that exceed the therapeutic range. Since there are few clinical studies investigating the pharmacological interaction and abuse liability of their combined use, this hypothesis has not been extensively evaluated in clinical settings. As such, our analysis encourages further systematic investigation of BZD abuse among opioid abusers. The co-abuse of BZDs and opioids is substantial and has negative consequences for general health, overdose lethality, and treatment outcome. Physicians should address this important and underappreciated problem with more cautious prescribing practices, and increased vigilance for abusive patterns of use.

Citing Articles

A qualitative study of benzodiazepine/z-drug and opioid co-use patterns and overdose risk.

Family H, Vojt G, Poulter H, Bailey C, Abdala Sheikh A, Cavallo D Harm Reduct J. 2025; 22(1):24.

PMID: 40016748 PMC: 11866653. DOI: 10.1186/s12954-025-01153-8.


Socio-demographic and toxicological findings from autoptic cases in a Northern Italy community (2017-2022).

Palazzoli F, Filippini T, Lavenia A, Balduini S, Attanasi A, Verri P Int J Legal Med. 2025; .

PMID: 39899056 DOI: 10.1007/s00414-025-03433-1.


The Impact of Longitudinal Substance Use Patterns on the Risk of Opioid Agonist Therapy Discontinuation: A Repeated Measures Latent Class Analysis.

Cui Z, Karamouzian M, Law M, Hayashi K, Milloy M, Kerr T Int J Ment Health Addict. 2024; 22(6):4004-4020.

PMID: 39722780 PMC: 11666779. DOI: 10.1007/s11469-023-01098-8.


Feasibility and acceptability of wearing a neuromodulation device at night in individuals in recovery from opioid use disorder.

Meads K, Huettner S, Amata D, Johnson H, Devine J, Warnakulasuriya S Front Psychiatry. 2024; 15:1481795.

PMID: 39676914 PMC: 11640868. DOI: 10.3389/fpsyt.2024.1481795.


Hypoxic effects of heroin and fentanyl and their basic physiological mechanisms.

Kiyatkin E Am J Physiol Lung Cell Mol Physiol. 2024; 327(6):L930-L948.

PMID: 39404797 PMC: 11684959. DOI: 10.1152/ajplung.00251.2024.


References
1.
Spiga R, Huang D, Meisch R, Grabowski J . Human methadone self-administration: effects of diazepam pretreatment. Exp Clin Psychopharmacol. 2001; 9(1):40-6. DOI: 10.1037/1064-1297.9.1.40. View

2.
Strang J, Griffiths P, ABBEY J, Gossop M . Survey of use of injected benzodiazepines among drug users in Britain. BMJ. 1994; 308(6936):1082. PMC: 2539956. DOI: 10.1136/bmj.308.6936.1082. View

3.
Woods J, Katz J, Winger G . Abuse liability of benzodiazepines. Pharmacol Rev. 1987; 39(4):251-413. View

4.
Heltsley R, DePriest A, Black D, Robert T, Marshall L, Meadors V . Oral fluid drug testing of chronic pain patients. I. Positive prevalence rates of licit and illicit drugs. J Anal Toxicol. 2011; 35(8):529-40. DOI: 10.1093/anatox/35.8.529. View

5.
Preston K, Jasinski D . Abuse liability studies of opioid agonist-antagonists in humans. Drug Alcohol Depend. 1991; 28(1):49-82. DOI: 10.1016/0376-8716(91)90053-2. View